<SEC-DOCUMENT>0001193125-14-005423.txt : 20140108
<SEC-HEADER>0001193125-14-005423.hdr.sgml : 20140108
<ACCEPTANCE-DATETIME>20140108162133
ACCESSION NUMBER:		0001193125-14-005423
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20140107
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140108
DATE AS OF CHANGE:		20140108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		14516664

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d656131d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;8, 2014 (January 7, 2014) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8 &#151; Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;7, 2014,
ARCA biopharma, Inc. (&#147;ARCA&#148;) announced that Dr.&nbsp;Michael&nbsp;R. Bristow, president and chief executive officer, will present at the Biotech Showcase 2014, taking place January&nbsp;13-15, 2014 in San Francisco, California.
ARCA&#146;s corporate presentation is scheduled for Tuesday, January&nbsp;14, 2014 at 3:00 p.m. Pacific Time. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, on January&nbsp;8, 2014, ARCA announced that the U.S. Food and Drug Administration has accepted the Investigational Device Exemption
(&#147;IDE&#148;) application that Laboratory Corporation of America submitted for the planned companion diagnostic test for Gencaro&#153;, a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. The IDE
allows the companion diagnostic test to be used in ARCA&#146;s planned GENETIC-AF clinical trial. The press release is furnished as Exhibit 99.2 hereto, the contents of which are incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma to Present at Biotech Showcase 2014&#148; dated January 7, 2014.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces U.S. FDA Acceptance of Gencaro Companion Diagnostic Test IDE&#148; dated January 8, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: January&nbsp;8, 2014 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B></B>(Registrant)<B></B></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/Christopher D. Ozeroff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">SVP and General Counsel</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma to Present at Biotech Showcase 2014&#148; dated January 7, 2014.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces U.S. FDA Acceptance of Gencaro Companion Diagnostic Test IDE&#148; dated January 8, 2014.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d656131dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g656131img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA TO PRESENT AT BIOTECH SHOWCASE 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, January&nbsp;7, 2014</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies
for cardiovascular diseases, today announced that Dr.&nbsp;Michael&nbsp;R. Bristow, president and chief executive officer, will present at the Biotech Showcase 2014, taking place January&nbsp;13-15, 2014 in San Francisco, California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA&#146;s corporate presentation is scheduled for Tuesday, January&nbsp;14, 2014 at 3:00 p.m. Pacific Time. The Company&#146;s presentation will be posted
in the Investor Relations section of its website (<U>www.arcabiopharma.com</U>) and will also be available via public webcast at: <U>http://www.media-server.com/m/p/3qtnqneu</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to
developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first
genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release and the
anticipated presentation contain &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding,
potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company&#146;s capital to support its operations, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro&#146;s
potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial fibrillation and the potential for Gencaro to be the first genetically-targeted atrial
fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational
requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the
SEC, including without limitation the Company&#146;s annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update
these forward-looking statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d656131dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g656131img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA ANNOUNCES US FDA ACCEPTANCE OF GENCARO COMPANION DIAGNOSTIC TEST IDE </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:65%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 2B/3 GENETIC-AF Trial on Track to Begin Patient Enrollment in Q1 2014 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:65%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, January&nbsp;8, 2014</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies
for cardiovascular diseases, today announced that Laboratory Corporation of America (LabCorp<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) (NYSE: LH) has informed ARCA that the U.S. Food and Drug Administration (FDA) has accepted
LabCorp&#146;s Investigational Device Exemption (IDE) application for the planned companion diagnostic test for Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), a pharmacologically unique beta-blocker and
mild vasodilator being developed for atrial fibrillation (AF). The IDE allows the companion diagnostic test to be used in the planned GENETIC-AF clinical trial. ARCA&#146;s Gencaro Investigational New Drug (IND) application for AF has been accepted
by the U.S. Food and Drug Administration (FDA) and is active. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA has identified common genetic variations that it believes predict individual patient
response to Gencaro, giving it the potential to be the first genetically-targeted AF prevention treatment. LabCorp and ARCA have developed the companion diagnostic test for Gencaro to identify patient genotypes based on these genetic variations of
the beta-1 cardiac receptor. LabCorp will provide the patient genetic testing for ARCA&#146;s GENETIC-AF clinical trial of Gencaro, which is expected to begin patient enrollment in the first quarter of 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GENETIC-AF Clinical Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GENETIC-AF is planned as a
Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to Toprol-XL for prevention of AF in patients with heart failure and reduced left ventricular ejection fraction (HFREF). ARCA plans to enroll only patients with the
genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company plans to initiate it as a Phase 2B study in approximately 200 patients and then,
depending on the results of an interim analysis by the trial Data Safety Monitoring Board (DSMB), expand the trial to a Phase 3 study by enrolling an estimated additional 420 patients. Medtronic, Inc. is collaborating with ARCA on the GENETIC-AF
trial. The Company anticipates that patient enrollment in GENETIC-AF will begin in the first quarter of 2014. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations
that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF
trial. For more information please visit <U>www.arcabiopharma.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company&#146;s capital to support its operations, the potential for genetic
variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial
fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether
they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s
intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s
filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g656131img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g656131img1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2@#4`P$1``(1`0,1`?_$`+X````&`P$!````````
M```````&!P@)"@$"!0,$`0$``@("`P$``````````````0,'"`0&`@D*!1``
M`00!`P(#!`4&"0H'`````@$#!`4&`!$'$@@A,1,B%!4)05$RE!9A<8%2(Q>1
ML4)RPC-#@S>A)#0E1;4V=A@*P6*"LE-4.!$``@$#`@0#!08""`<```````$"
M$0,$!08A,1('05$388$B0@CP<9&Q,A318J'A4G*",R0)DB.S9!46)O_:``P#
M`0`"$0,1`#\`N)]SO=>7$<M<+PQF):9N\P$B9)F]3E=C49]%6/[Q';(2F6,D
M/;;:51``42/P5$717ZK/JYCV6SH;#V=9A?[A9%F-U2O+JQK5MI\73Y_Y7R,H
M[#[>W-TUS\Q^EAV_E_MKS(^![D^XR]FD\O)V0Q/5<15;KVJJ)'9%2^R,=JO0
M!1-_#S5=O/7K,ROJK^I+<&K?Z/<VI8ZN2ZG&SZ2M*KK2VG:;Z%RCQY4,S?\`
MI.RL6U%7<.PVDN+ZJ^WY@YP^4.Y-R:U#>Y6R_K<DL,*B.5P[H\Z`@XBI7_9<
M`MQV\T77;]+[O?57F9\<">Z]:7J/X76SR?)_Y/D?F7M'V(H2G#3L:D&T^$O#
M_$:2^4NY4);D-KE3+_51]UA$1VO]GTC)#(E*O\@$55?R)OKQS>[GU6VLF6%;
MW7K7JX]Z76ZVN,4VN/\`R?8>,-'V-."FM.QN*3Y2\?\`$$Y>Y3N,HI@R?WGY
M%+%LE0`GQZJ5&/9=]WHSL#I,"1/SZZOC?55]2VBZT\N>X=2R[-N;7H7G:Z)4
M?LM)T]Y^Q#8^S=4Q'Z.#CVITYKJ3_'J)".V+NQ7ER2N&9HS$J\Y9BG*@2(6[
M5=DL9D4603,<R-8=G&!.LVA(@,44@VV5->R_Z6?J\Q.\N7+9.\[<=/[B6+?7
M&*=+.1"BITOD[GC**\^'(PMOOMS>VK..7B2=W3IT;?/HK\K?LY?F/81P]DV-
M53Z_#Q_@UO0G)I.2I*G%>3\O<8O=*\.0/4/]9=20#U#_`%ET`T>%WI\03^\2
MV[)&)\X^6ZCC1GDB5)%8BT/2XXV^YB;;R2%F?B>/0R&[(VU:Z!BFB[[[IH!W
M'J'^L7Z?!?TI]"Z`'J'^LN@(^^X'YE_;YVOY=>8IS+0<\XW%HG8S+N=L\'YM
M;<;3EE1H\H'*K-H$-ZHL&@21Z9D);"Z)!]I-M`(*U\]3Y>4MZ-$JN1.0KVRF
MN@Q#J*7B+.;&UFR'%V;BQ(3-9ZS\EU?LB"*2Z`,]G\Y+M'QYAFPS6B[EN.Z%
MYUMM,HSGMRY)H<<#U/L$]9O5AML@2;JG4GDF^V@'T<&=R_!7<OC3N7<$<JXE
MR721B:;L"QZR`[*G>>'J:8O*24,:YIGW$WZ1DL-=>R].^RZ`6_U#_670'A)F
MLPHTB9,E,Q(<1AV3+ERGFX\6+&8!7'Y$F0\0,L,,MBI&9J@B*;JN@(R^1OFZ
M]G^(YHO&7'E]G7<GR<+[D7\$]N&$6G)TL939DV3+MO7BS0$($GM&U)=`/I5-
M`?+9_,;Y6I*MR_N/EN]\,2@99*3(GL8IA5E/8BB*D;[N/UN5RKH5`$W4/0ZD
M3Z/#0";<=?/1[)<]S7'^-YS?-&`YQD63U.'QJ3-N-)4!R'D5S8LU46OLW(,^
M8==T3GP`R=`$#?<D1-`3'J9HJIU+X*J?P:`QZA_K+H!&>X7G;#>VKA?D/G/D
M-^4&)<<X_)O;*/!5A;*S<0@C5]/5!(<::>M+:QD-1V`(D0G'$W79-`=3A'F'
M%N?.(N.^9\%D/.XGR1BU7E-,,E6O?(C%BRANUU@C+CK8659)1R/($2(1>:)$
M70"I>H?ZRZ`WZR]/?J7?KVW_`"=.^V@*^_+86&2\U\GRI7JR#_'5]&,T0S$6
M84]V%%;ZEW0`;C101$\/+7S<]ZLC6-=[W[BQ[7J7[L==SH+J;DU&.1<2BFZM
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M6A7@[@N7?0L79.W%6X]7AX+^MC2^2N-8N/`]#>1F1>(&TQIGI.-3H8_Z,1].
MSUCTDG7MN+*+M[1;[:1]V^T>G;;P_3OUR=Q1C2:BJ]%Q?JC&G@I52,F:%N"6
M1)1C-QQH\&_"27"OO$1XH&?C/-'&LJ,KK!)FE(P)JA-H;<J8W%D`FR#U`ZP\
M2+]"HNL(]C7GZ#WSVGC92DE/7\=4XITG*;E%OFTVE5-^!VO<M^QF;.SK2H[:
MLMKQXTYK\RP%LB>">")X(GU(GEKZ/%+K2GY\?Q-.HJD4O8#4GD)[RSR;BW"_
M&&?\MYO-"!B?&^)7N97TDW!;7W"AKWYYQV5/9"E37&A99#^6ZX(_3H"AME')
MO<)VS][W`_?;R_%?@Y#SQ.I^Z*-&;61N[QAG-W9T]EB$@#1%;=@86V,=(Z)T
MMLFQX;:DM48T+^F/WU3E5#29103&K"AR.HK;VEL&"0V)M7;PV;"!):)%5%!Z
M+($D_/J"HZ^@$[Y=I:K(N*.2Z"\KX=M2VN`YA"LJNPCMRX,R*]06".,/Q7Q-
MAT"5=]E'P5$5/+0%)[Y`M/5S_F&4YSH$6:Y1\2\G6%0<MAJ05=8,C406I\57
M1+T)C<24XV+@[&(N%LOBNI+:*E2\??T%'EE)9XSE-16Y%CUW"?K+FENH;-E5
MV5?*!6I,69"E`XQ(:=`ME0D74%3YE#'&\IN_EZ_-LR''.';"?78EC/<<''$W
M'F)+ONF0\8Y?D4)@\5M6.I`G#7P+@5CD>ZM/,-F.Q;ZDNZ50ORN*(*2DJ"`]
M1$9*@@`"BDI&2["(B*>*KJ"DIR=_7>_S3\R7NKINPWM2OYE1PW89PN!OV%5)
MDQ6N3K.JD.KE6:93.B$W)+C?&6(4AZ/$0O2E,QE?<0B-L1DM44E5EE[LW[*>
M$NR3C"KX]XFQR"-L4*-^-.0I<..N7YY=B`++L[>R0%>9@*^B^ZP6B&-%:1!$
M=]R*"H=Y]*+NNZ>2[KNGZ?/0$,_S8?E]4W/F#PNXOAG!^KNFX8O<9S.D<Q:`
MRW=<H4V/7L"?,Q*U881M+BYCLMK(K7W-WFW&5:ZE`]D`F(J)<BPJ*F?+B2($
MJ=65\N3"ECT2H4F3#9?D0Y0_R9,5UQ0-/H)%3Z-`=#0%=WYW60\D=P`P.R[A
M`5L+#!>+LK[M^=&63,O1PW`6'6L/QMY&4+:QN[`Y$IE@]O45EI=O)=`<7_MU
M>YA,UX.Y&[9KV=ZEYQ#=CFF&QWC57G<!S9\RG1XZ&J%[O29.VYN*(J`,P4WV
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MSAXZT[*IC9,8VZ53K*B5>-77[CH[A=NVY2N6ZS3_``H)#R=B$VM&4F/8;'%I
M5<-;VRD1K6QDJ:[D_'&7(5J,I[]6Z-J>ZKNNL/=T=IYEB.1<T?1H7K#@YSRY
MSCZ\)/BY6ZOSJU5/P/W]O9EMOTK]Z]Q^5+A]WV8P6%56$;F3CQZ:RZ#J9SCG
M4KSK9.)_K:.F^PN+X>*>2;:]<>B:1JF']0>T[[G&XY:QCS^-KJZO7N*LJ?-3
M@Z</89GNSLRVAG17&*QG2O\`=)RB^TOYU_CU]`T52*3X.AJE]W(QJ00R_-.O
M[+G3.NUWY<6'R7OB'<MR#7YKS44`C*12=OW&D\;R^.8C9;-1LCF5I`*GX$L1
M1V]O0"&?]P#VMP,Q[0\(Y?Q*B:CS>VB[@5S\:'%7:-Q3E#5?C<V**`G4$.AM
M(E:Z([=+;?J+]:Z$IM<A</D6]RJ\[=D]'@]S8>^9GV]VI\:V:.O>I*?Q4VUM
M,%L'=RZE#X0Z<)%V\?<O/Z-""9W0!/Y#_P`/\[_Y+RK_`'#/T!1.^2KS1Q5P
M-WOMYYS'G=!QUAW[K^1*-<CR624.K&ULY%.4"$<A&W!;=DC&<Z>K9%Z=M_+4
MES_26K.4OF]]AG'=`]8X_P`X47,&6/H,?%^/.)`F9?D^67DI1:JJ2`L.,M;$
M=L9KC;7J/O`(=6^RKL*P4OF12=CGRNN<N=^[2\[^N]7%2XU@V?)=ERYB7#EB
M0'E5SDLJQ6QQTLFACUC18WC0@R0QWMIDMU@4(&VU7<3U,G%^8?R9;</]D'<]
MR+12#B7M)Q+DD6GEM$8O1+/(F0QN++8(%$@?BN6_J`2*BB0HNA!60_[<3CNL
MR'NHYCY`GLMR9W&W##4*C-\4,X\_.\C8@3IC1JBJ+_PNF=9(D\5%]4\E74ES
MY4+G6VWA]7AJ"D&@!]*+]*+NB^2IH#.Z_7YKO^GZ]`<'*,GH\+QG(LOR6<S6
M8]BM':Y'>64@D!B!44D)^QL93I*J(@LQ(Y+^7;0$1ORJ,9M.<87<MWY\E5)G
M==XW(-K7857V3#KBU/;[@[DG&L0HF!?ZNFOM!!XG!3V75:$O'PT!7ZX;LI?R
MN/G%3\.M7'ZSCE[DB?@5B;^[$:9Q!RX^S*Q6W(3Z0<8I'K"$]U+X(4,D39-]
MI+:)HO*;HOD2$BHA(0JBH0EOTDBHJ^R2)NGUZ@J/3^R_O/Z.@('\AD`'-/)(
MF]&C@G(&5(X[)<]/H#XY,4ND$0WG/S""[Z^=S7\JWA?4%N:=R^[7_P!'J'C_
M`-U<-M\;%C?VQ@=*5?V=G_IQ'L\2WN/Q9-:Q70['*+M\@"/U._"ZILEWZS]`
M%.5*8:3=2)WH!!\53;7L`[/:[M;!SK-RU9U7-U[,:M^EZK>,E*/2[K5?A4HO
MV))F)MT863%2=>F*KX<?M^(0\@XCSO!\EM[CC>"F:89-M7W$8I9++EA0S99K
M)D5+L=QQDIS##KJHRXQU[AX$FZ:QWN;L1W)V%O'-S>W6%<UG8]W)NY$K=BZE
M<LWISE*6/;XU:MMN$>+JDC]+3-Q[?S]-A@:RY6<RU;45-_RI*J?\14\+H,XN
M)5;-SN&6'T#<P&D"\DM,2K&6WU/-UP,MN/\`N8/$"(;CRALBJ@INJ:RWV_VS
MOC7KN-J^][;V_M>Q<4K-K4)=>1>ROFLMIKI@I55'QHO,Z[J^=H=BS+'T^=R[
M>;_4O&OS>\YG+-]CTJ78LV<*QQB]CF8R4;<6SJWG/%>OT7B9DL`ZFQ(376)(
MN^WBFN#WAW!H-S-RK&NSR-%W%",E;BYREB76JKJHG^B5*KV4.1MO%OPE&Y;E
MUQ:K1KC]D,AI9`N<Q<<`+[,EI<\QOTW6#ZQ-4M8Z[J!=+K:[(GVA3].O7UM.
MZ\GO]M.^KZO4U7'KTM]#?[FY5Q7]E^'L,MYF,UM'/DU27[=_D3OE]HOYR_QZ
M^A]<C4X^2;-B5L*98V$AB'`@19$V=,DFC<>)"B-'(ERGW"41:9CQVB(B541$
M30%<+M)X(8^9SW$]U'?AF?(G-/&^'-YRO!_;C:<0YW-X\O'./L,C)'NW7;>!
M%>E/55IUQ7#:;4`.6\^I[JFV@'[YI\I_C7.,3R+#[WN?[V[ZIR.HG54VHR?N
M-R.^Q^<,I@@9;N*6=".):P`DJ!N,.(HN(.RZ`KN_)VY4R#LT^8YEG;7R+(.I
M@\B7&2\&91&DJK,5C/L4M)C^$V2BXH@!SY3#D9LO#J">.R^.I+>E4+N/BG@O
MFGG^?4%3YA/Y#_P_SO\`Y+RK_<,_0%(KY"%+37_?_P##KZHJ[NO<X<Y1-R!;
MU\2SA&8R:%!,HLUE]@B%"5$51WV5?KU)<^0^SYY?RV:'"Z=CO0[=</A8I%JI
M<>+SABF&0&ZFO@J])`:/E&IKZP(\>L=C3C%FT)D6Q13:D?:%PE@I?,D>^3=\
MPL.\+A/]V_(]T#_<'PS60:[)BDO-^^Y]AX($.ESYH?961-'I2)9JGE)$75\'
MDV`?QWM<1S^>>T?N'XAJ&U=O,XXKRBOH&.G<I%_$A%;4D84W14.1:0&@3\I:
M`J<?]OAR_!XQ[T<QXMR9Q*E_F?C2TQ6N8F[17$SC!;4<AB4[B/H)A.=KV[)I
M&_`B=%!7VMDU)=X%VKS\?KU!2^8-`91-_P#)X?3XKMH`MXKF&)YU3-Y%A624
M>6T#TNQ@-76.V<2XJW)U1.?K+2&W.@NO1CD5]C%<8>$256W0(5V5-M`1$_.5
MY:R)[BCBSLPXOE$O+7>OR+3<9QX\8R697\;L64%S-;5X&E]5J',1YF(1+L),
M&_X["NP"GXC\J#C'",6Q_$,=[GN]Z@I,<J85174^.=QV145#`8B-(),U--`@
M-Q*R"3Y&8,MITM]6WCYZ`@=^>#\OB!V\T?%7<!AV>\R<D0[VWD<=Y[D?+^=3
M^0LDJYP15LL*=BW\Z.S+AUY-1YK0-D1"+HCT[;[:DO+%7RO^Y5.Z?LJX=Y$G
MS`EYA1TR<<\A(AH3X9C@P-4\N3)3J4T<MZX(TY%7S23OXZ@H)!O[+^\_HZ`@
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M*3*%QBUL9EE5)UHOHVL*2ZXV`(J[($Z(A-*B>9].^N5K_>+3=1_\UI&1DRNV
M;^9=OXBE+J5J4;DG.5NO)R\:</*A=9VK*W=Q[UF"71;BG1<^"K7WC6LXY2.W
MAC"FOK(.&RK5?.(E)]E@>I1@NEU"X]#W\6T55)G=>E=E5-:<=Q>]"US#N6I7
M)7<GC%2D^I]*X))M/P.^:-H'[:Z[RBEU.O+S"EP%1VF=<XX!"A,NO>Z9##O9
MKJ;DW&KJ9T9\N4X:(@``^D@^.R*1(B>.NM?3'M76]]]\]!LX,)/'QLB.5>NI
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MY>K3466UC+=FY%:R6LLYXD<,X9.FH."!B)^SJ"I\Q6.['O=[5^WK`N2JWD_F
MW`:7+H6(9##:X^9R"!89[-M;"CDMU=4QB<!V1<A+L')+:!ZK38"+B&9"'M:$
M%-?Y-_<5Q/VV=[N.9[S1E$3"<)O,&S?#'LIL?4.JH[?(1KWZIRY>C`\<2O??
M@JR<C96VC,2-1#<DDNYHO3X[F_"'<G@>01L0S#`.9..\@@3L9R;\,7M1E=%+
MA7$!QB=3V9UTF2TRY)@2556G%$^DD)$\EU!24?.XWC#E[Y-O?W2Y?QG+ECBL
M6U=S'B:UF..-UN=<86<I8U[Q[D#P](2WX#!%`F#XD*HS(%%)174\"U*+1;:[
M9_F?]F'=!C^,3<4YGP_$\XO`@1I7%N>W<#%LWJ\@F*#14;$&U>BLWQ+-7TV'
MX)OM2$Z538BZ4@J(:?F>_*=Y?PWF9SO>[%JZP?OF,GC\BYAQOBG2UE6+YQ`F
M!9R,\X\@IZ8W$&RF-J]/K`_;`\1DTVZVX8`)ZF2%=C'SAN"NX:DK,`Y\O*SM
M\[E:9IFIRO#>02+$*');>*`,2;?$K*\2)'BI-?%2<K99,RXKA*"(X"":B"5B
MPY1XRJ*LKNUY&P*LI0:5\K>?F..Q*Q&43J]7WY^R"-Z:CX[]6V@(`_F<?.MX
MLPW`<MX-[/\`+(W)_+V4UL_';?D7$NNQQ#CNNG,NP[%VDMV!)O),P>CD;<;W
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MH-B[PI(&,-/N77K64]@&A+T4%6'B+=`W70GJ97<^2;\QOC_L]S?..*.=+QS'
M.&^7GZJWA9:;3TNKP3/:QDX"3[EJ*#[\>BOZLP8D2&VR1AV.T;B="D0R6=*+
MA?\`U6]L?[N?WK_]07#W[M/B?PK\<?O!QG\-_%_</B7P;XE\1]#XS\._;^Z;
M^\>E[71MXZ@J,\Y=ON$\X5T=F^1^LOZX7QJ,FKQ#XA#`R5PHLEIS9JPKW#3=
M6CVZ5\145W76O7?#Z=-C]]M,C+<<?1W#BQG'&S;7"=A/PDJTE3QK7V'9]N;O
MU#:>1&6(Y2PW+JE;^5OV^-1B,CY?W)$*8ITV>XC)C":JP[+C6T-[HW%0]5AI
MF6"$B)XHA[:]>^3_`+;6_,+*C>T77M-NXT95MSE')4VOEE))=*DU1RIPKR,M
MOO=I%R#C>QIIO]2X4KXG4B]DO,L9YMY<UPHS!X'^I7[E.HP<1S_Z'DNW^77Z
M.!]`W>G3<J>99U[2'=FVVV[]75U\8G&?=;;TXT_;7.E^'"GYFDKLDYED&3J9
MKA(NJ\KR'Z]SN)D2ENB^X[^"KJFY]`_>ZYD_N5K^CJXNOIXWOA5QMR7Z?&O$
M\X]VMN0CT+&N)+[OXG/8^7]R3.EHMKGF)Q(QGU//PXUM,>$57VU9CN,16R-?
M';J/9-<7!_VU][9F7&>NZ_@6,5<U9C)U_'B<B?>?`L6UZ&&G%)4K3W>/D/IX
M/[?,,X.KI+=(+]K?6;;86^36(M^_S``O4&+':;W:KZ]MSQ1H-U5?$R)4\/8#
MV*^G;8O8;39K0DLS<N:H0OY<U\=SI22BO",%3@E1TYF(MU[QU#=5Z-N\W'!C
M-RC;5>F+?'V-L7=]AB7'>BRF69,64R['DQGVP=8D1WVR:>8>9-";=9>:-1(2
M14(55%\-;%\5P?,ZR^8CL#ML[=:AKT:S@'A:O95%56X?%V%,A^=4;I$'==_/
M0=3.QC'"/"V%9`.6X7Q#QAB.4I%D0AR7%\$QBBO4A3>A9<5+6KK(LWW>7Z8^
MH'7TF@INB[)H0'/)L6QG-**PQ?,<=I<KQJW9&/:X_D57#NJ2R8!P'@9GU<]F
M1#E-`\V)HC@$B$*+X*B+H!-H/;CV\5K?HUW`G#$!K_XHO%^%,!^D`I4'=-34
MGJ?F;)VY]O8V<"Z#@CAQNXJID:QK+9KC3#6;*NL(3HOPYL*:U3A(BRXKX";;
M@$A@2(J*BHFH(/INN`>!\DR"PRS(^%.)LARFV<;=M,DO>/<4M[VQ=99".TY-
MMI]5(G27&V&Q`5,U5!%$3P30'F_V]\`R6U9D\&<.OM%X$T]QGA;C9(J*BH0%
M2J*^"Z$]3#3A'&O'/&<.=7<<8#AN`5]I-2QLH&%XS3XS#L+#TA82;,B4T.&S
M)EHP"!ZA"I(*(F^VA!KF'&7&W(A5I<@<?81G94;LARG+,,7H\F6H>DH`RCKO
MC$*9[@[(1H4<5OI4NA-]]M">IA6+MX[?RFP+)>"^'?B-7*C3JRP3C3#1G5TV
M&\$B)+A2PIA?C28K[8FV8$A`0HJ*BIH0+"OBN^Z[[[[[JB[_`%[^>^@$%Y8[
M6>VWG53<YAX+XMY&E$FRV.48=33[=4VZ=AN%BC:"J(OLJCR*B^6@&_P?E:?+
MTKY`26.T_BQPFCZP8GP[BU@BN_5M\-L[B77*&_\`)5KI_)H!S>%=OG`W&\5N
M'@'"W%6&QV10&QQW`<8JS04\D)Z+6`^>WY270FK.[F'$?%'(<NIL.0.,>/LY
MG4++\>CF9AAV/Y))IH\EQIV0Q5NW%?,.`R\XR!$+2B*J*>'AH0%R;VY]O5DP
ML6PX&X9G1E\V)7&.%O-+^<#I5'0GJ?F*;C^/4&)TM;C>+4=3C>/4T4(5114-
M=$J:>KAMJ2MQ*^M@M,1(<<")50&P$4557;QT("#D?!'!^8Y%(R[+^&^+,KRN
M6U&8E9+DF`XM>7TEF&WZ41I^VLJN3.="*U[+:$:]`^">&@/F>[>N`)#/N\C@
MOAU]A=D5EWC/##:7;RZ@*F42V_+H35^9Y?\`3?V\_AO\)_N(X>_"WXD_%GX:
M_=QB/P#\4>X?#/Q%\(^$^X?&_AO^;^\^GZWH>QU=/AH0+,?VB_G%_&NJY6;<
MIJXU\:^W+D_>B8MQ_3P--D\M6>*:YHGJ?/A7[D#9/J3^#7AZ<*]7&K]K_B3U
MR\S.GIQ]OXO^)'4_LD#7DHQ2HDJ?B>/C7Q!^7]&E%TJ*2Z4Z^\5X4\`:D#->
MYU^QRK,.(^(\?R._I;#++*9992-3<2:Z"U@E:/5;OVS44VB(74ZQ`R(11!5%
MWWT`[2CFT<ZMCKCMA7655#!*YAZKFQY\5KW``C>Z^\1G'6_58$$$DWW3Z=`$
M#E6BE9;!HL9I^3I7&UZ[>P;:,]5RH@6U["KO4.75,1'9#,B3'=%>HO30AW%$
M)%'=-`*GN@-[F7LMMHKCAJ(HB`/MN.+X"*>&ZKY)^;0'-JKRDO1?*DN:FX&*
M[Z$DJNQAV`QGO']D^41YX6C\%\"5%7;0!<Y'S^DXOPJ_SJ_1YZLH(HONQHGI
MK,F///M1HL.(+I`V4F4^\@@A+MMNN@/HPK-J+.Z*!=TTV"X4JOA3YM8Q9UUC
M-I3FL`^,&S2NDR6V930GTDG5LA"J:`2KNDR=S$^$\LM(=G;U5R_[A5X\_26#
MM98.W=E*"-#8"0U^T)G8B-QM-NL`VW30!CX<@5F$X1B&`3LAA3<RB4;%C?09
M=PS*R)^UL^JRM9<N*])<GEM)DDBD2+[(^?AH!85\//0'%LLDQZF?@Q;:\J:V
M59RPKZZ-.L(L61/L'$W;@PV'G0=D3'$^RV**:_5H#[Y\^!50WK&SFQ*Z!'#U
M)$V=)9B1&`W1.IZ1(-MIM-U1/:5/'0'R!?43DN%`"[J#G64;WVMAC90RE6$+
MH1Q)<*.+RO2HR@NZ&`J.WCY:`^BRLZRFBK.N+*OJH2&#2R[*;&@QO5=79MKU
MY3K32..+Y)ONN@/$[RD;LF*4[BJ"YDLE)C5)6,-+.1'`$,GV8*O)*=90%WZD
M%4V\?+QT`(%Y2VKTV/67%78OUSJ,6#$"PB3'8+Q*2"U,;C/.E&<)179#05W3
M;ST!U/T+_`OA^?ZM`<A,@H5MPQ]+NI*]<B'/;IAL(I6AP&S]-R:,$7%DK%;/
MP(^GI1?!5WT!U]`>G]E_>?T=`:G]LOYQ?QKH#70`T`-`#0`T!A5$44C)!`44
MC)?(0%%(B7\@BF^@(\,4JJ;ES/N7>X7D.R]TXEH5F8?2PS=<BL7E#C1_YY[V
MZ!MNN5,F2"*<<%_SQYSTRW%.E0%V[4,&DX=Q_<6<FI+'8^?9C<YA38NX*LEC
MU!8$VS0P#8+VF)#E>P#ABOB/6B>::`2S"**CY*[FKC-QF'/HN+7K&AI;FRD@
MY.R[/):./VZUY>P#E+A\!U&&&F!%IM!%53<B)0#QSQ/N,UY.XMX#KYDNNH<K
M;G97G\F$\<:3.Q>C-2^"`^T2.@Q/>9('ME]H21%^K0'.P(H\SNOS:/A4*/6X
M1@/&]3AEXW5L!&JG;T9HS(<(FV$!DYM:#IINJ$:"*^/CH#G=Q%2QR/S%POQ$
M,BP=:G37,RS&`$]_X6QBV/FX^T,BL`DBE*LI+9!ZCB$OLB@[:`UP*DAEWB\B
MV&$UL2HQ'%L!JZ'*FZ:(U"J964RT9D,1#CQ@:BE8,->)IT]:>EN7GH#3N*B7
M'*7,/$O"N/2O=F:EUWDG+9_0$@*J%"<2+7/FR:$V<@=G%8$MT5UT-_!-`8G\
M8T4;NDXLB836+#_`N*7>49[>`9O64]RX-^)4CD-F2E(GV=H\CA_M54E!5V1`
M1-@%LSS-K"QS:JXBQ.P^#VLVD?RK-\G`VT<Q'"H[BL=4(W?V+-W=R-VF''$Z
M([2$ZJ*0CL`W#C6MP/D_N(/*\;KX3>$\01GL=QNSDN*],SKD&6W(D3KDY4MP
MY5P]4P0<<%XE,T%!<\!)-`&[O50)F#X_C,1E^VRC.KV)B.*T2N)[D,B0^U(G
MW90A3=V=%CMBPVX2J+`O$HBA*JZ`5'C_`+=L'Q/\$7]M7-W?(>(US3*9:\_*
M1_WI:\8!QH[`O^[C55[&[45GIZ6P3?[1*N@$([J:.3R;GV"<.8ZX[8Y+D#L6
M\MGI:C(K,$Q2J>)7[)J(*`R,VW>(C<<<57'09!H5025%`3]W#,=RWFZSMJN7
M(IN..WJBEQ\_Y%;?,<@RZ_&#(6Y@K=(76;YQ^J/[!C[M'0@:0.IM-`+;VBXM
M7>CGO*359`QZ3R;:1["GQ.O%M@*'"(QR&L:<D007J9DW(@X_U&B*XB=:;]2K
MH`YY#R!79=?9VS/O"Q_B/B8DBYQ:1Y1Q966Y0C*2G<9CRV#"0%-5-$(2`9(7
MID@Q:0NCJW`(G:M1TE_=9]S8%/7T+V<3%AX9CS+;,=^HP&K>2#&G>Z@B$R5U
M.BJIN(@BX;9>:[Z`>G^?ST!Z?V7]Y_1T!J?VR_G%_&N@-=`#0`T`-`#0'FZR
MS)9>8?%29?9=9<%%4>H'@)LQZAV4>H"5-_--`(+AO;A@6'-1X`3<HR#'JZV?
MNZ?$\BN!G8U463S_`+S[TQ5L1HK4]]I]>MLI:O>F2=2)OXZ`7IYM'VG624A1
MUEUE2`N@P%QL@Z@)$]DQ0O979=M`)-Q9PGA7$4)R+C:6MA(=>FO?%,@G_$9[
M*6+Z2)C,-4;98A-27!%7?2`2>Z1ZU+9-`=G+.-JG*KNFR@+*XQS*:&%9U-?D
M./O1&K`:>X%L;"O<]_ASXQ-N$VA@?I^HR?B"HN@/MP_"\0XQH':JCCLU5;Z\
MFSM+.?*]698S)'4Y.M;RUE$)S);GBI..*B(G@*(GAH!IG#M"O-7)?+?.#&47
M=&`WKO'^"V./R*Y7TQFGC`U8];-C"L8RMV#A-F!^FA@:*0$F@'?8;@^-X%4G
M3XW"*.U(F2+*QF27G9EK;VDPE.79V]C((I,ZPDFJJ9DOT[(B(FV@";:\+8M;
MV/(=T=ADM=>\DU-936]U67!1;"IKZCI6''QMX&=ZIOU&T(T3KZU\]`&[#,(I
ML'KG(=:=A/FRR8<MKZ[F.6=]=OQF`BL/VEBZB&^K$<$!L400;'P$4W7<`AW_
M``'@V2<CN<EVCN0':2JF'36--'N7X>.VL."75&;M(,86WIS(](]3)N>@1(BJ
M"^.X'U<7\&X-Q,=D_C@6<R58V%E8!)NYJ3CK%M70=FQJID&F8L%EY&FP,A!7
M7`:%#-41$T`9;CC?&;[.<6Y!M6YLJ\PV%90J!DY7^JHAVNR2K!8/IKZEB+:=
M(.J>X)Y)H`^Z`3FHXPQNFR_-<\BG:.93G46-"M+.5/5]R!!AM>C&@T:>D"5D
M9I/:1$ZE]1$7==M`%,NWS`@XKN.(8AWD/',@EOSKBP8LD+(+"=*L&K&5,F6#
MS!A*=D/,B!H;:BK0].V@%'PO"J#`:6-1X]'=!AAN,#LN8^<RRGE$CM1&'K&<
M[^UDN-1F0;!/`&VQ011$30",KVL\:F>>*_)RF0UG\NTGS8K]XX4"EL;?K]YM
M*.N1CW1NS!'%%M]\7G`!5$51-`*GQWQMC'&%!&Q_&FYCC3$>-'=LK60LVUF-
MQ&_2C-2)9".T>*WX-M`(--HJ]([JJJ`?M`>G]E_>?T=`>J^:_P!1YKY^?G]/
MY=`8^[Z`'W?0`^[Z`'W?0`^[Z`'W?0`^[Z`'W?0`^[Z`'W?0";<M?\#VG^'W
M]9%_Q'_X1_K?]I_T/RZ`3#MZ_K\D_P#S_P"4;_`_^K^U_MG_`,_ZF@',KYK_
M`*/Y_3Y_I_+H#'W?0`^[Z`'W?0`^[Z`'W?0`^[Z`'W?0`^[Z`'W?0`^[Z`'W
6?0`^[Z`V_D?V/VO_`$>7_N_\-`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
